All news (page 2)

• 

  19 February 2026

  Repsol Reports €2.568 Billion Adjusted Net Income

  Net income rose 8.1% to €1.899B in 2025. Adjusted net income fell 15.1% amid market volatility and geopolitical issues. Resilient performance supports strategic goals.
• 

  19 February 2026

  TechnipFMC Q4 2025 Financial Results

  Subsea orders hit $2.3B in Q4; full-year orders $10.1B. Shareholder distributions $188M in Q4, $1B annually. Revenue $2.5B, net income $242.7M, adjusted EBITDA $440.5M, margin 17.5%.
• 

  19 February 2026

  Statkraft's Former Employees Advance Biofuel Tech at Tofte

  Statkraft shifts focus to core technologies, transferring biofuel expertise to a new company led by former employees, aiming to commercialize HTL technology for emissions reduction.
• 

  19 February 2026

  Merck Reports Positive Phase 3 Trial Results for ENFLONSIA in High-Risk Infants and Children

  ENFLONSIA shows consistent safety and efficacy in high-risk infants over two RSV seasons, supporting expanded use for children under 2.
• 

  19 February 2026

  BENEO Names Dr Uwe Boltersdorf as COO

  Dr Uwe Boltersdorf, with 20+ years in management, becomes COO, overseeing operations, production, and sustainability, while retaining his role at CropEnergies AG.
• 

  19 February 2026

  INEOS Secures €300M French Grant to Decarbonise Lavera Site

  The investment cuts CO2 by 331,000 tonnes annually, secures jobs, boosts competitiveness, and supports France's industrial and climate goals through electrification and carbon capture.

• 

  19 February 2026

  AGC Biologics Gains Anvisa GMP Certification for Seattle Facility

  The Seattle site can now supply biopharmaceuticals to Brazil, enhancing AGC's global supply capabilities and expanding regulatory approvals to over 11 countries.
• 

  19 February 2026

  ORLEN Group Reports Strong 2025 with Record Investments

  In Q4 2025, LIFO-based EBITDA hit PLN 12.2B. Annual EBITDA reached PLN 41.9B, net profit PLN 11.2B. Investments of PLN 32.6B focused on energy security and low-carbon sources.
• 

  19 February 2026

  Asahi Kasei Pharma Partners with MAIA for U.S. Teribone™ Development

  MAIA will develop and commercialize Teribone™ in the U.S. to address the growing osteoporosis patient population, expanding access to proven bone-forming therapy.
• 

  19 February 2026

  Asahi Kasei's Thin-Film Hall Elements Earn IEEE Milestone Recognition

  Thin-film Hall elements, launched in 1983, revolutionized magnetic sensors, enhancing electronics and energy efficiency, with over 50 billion units shipped globally.
• 

  18 February 2026

  Toray's Ehime and Nagoya Plants Achieve ISCC PLUS Certification for Engineering Plastics

  Two plants gain ISCC PLUS certification, enabling use of biomass and recycled materials in PBT and LCP resins, supporting carbon footprint reduction.
• 

  18 February 2026

  Iberdrola Named Most Sustainable Electricity Company for Seventh Year

  Ranked 17th in Clean200, Iberdrola excels in sustainability, energy security, and competitiveness, outperforming fossil fuel firms and earning top ESG ratings.
• 

  18 February 2026

  Johnson & Johnson Invests $1 Billion in Pennsylvania Cell Therapy Facility

  The new facility in Montgomery County will boost U.S. manufacturing capacity for cancer, immune-mediated, and neurological disease treatments.
• 

  18 February 2026

  Johnson & Johnson's RYBREVANT FASPRO™ Gains FDA Breakthrough Status for Advanced Head and Neck Cancer

  FDA grants Breakthrough Therapy Designation to RYBREVANT FASPRO™ for HPV-unrelated head and neck cancer after platinum-based chemotherapy and PD-1/PD-L1 inhibitor.
• 

  18 February 2026

  PureCycle and TOPPAN Partner for Sustainable Recycled Packaging Solutions

  They developed a snack bar wrapper with 30% recycled content, targeting thermoforming applications to meet regulatory demands without compromising safety or performance.
• 

  18 February 2026

  Merck and Mayo Clinic Collaborate on AI-Driven Drug Discovery

  The collaboration combines clinical data and AI to enhance drug discovery, focusing on gastroenterology, dermatology, and neurology for tailored therapies.
• 

  18 February 2026

  Baltic Power Completes Foundation Installation for Offshore Wind Farm

  All 78 monopile foundations are installed at Poland's first offshore wind farm, with electricity set to be supplied by year-end. Construction completion is expected in late 2026.
• 

  18 February 2026

  Lilly's Taltz and Zepbound Show Superior Results in Psoriasis and Obesity Trial

  Taltz and Zepbound together improved skin clearance and weight loss in psoriasis patients with obesity, outperforming Taltz alone in a Phase 3b trial.
• 

  18 February 2026

  VolagHy Releases EIA Program for Kuopio Site

  The EIA program for the Kuopio site outlines environmental, social, and land-use assessments, moving the project into the formal evaluation phase with stakeholder engagement.
• 

  18 February 2026

  Asahi Kasei Pharma Begins Phase I Study of AK1960

  AK1960, a selective endothelin A receptor antagonist, shows promise for treating refractory kidney diseases, aligning with R&D strategies for unmet medical needs.
• 

  18 February 2026

  NEXTCHEM Secures Licensing Deal in China for NX CONSER™ Technologies

  The technologies will enable efficient co-production of BDO and DMS, supporting biopolymer production with improved cost, energy efficiency, and sustainability.
• 

  17 February 2026

  Mitsubishi Chemical Transfers Synthetic Resin Emulsion Business

  Mitsubishi Chemical transfers its synthetic and acrylic emulsion businesses to Konishi, aiming for sustainable growth and competitive advantage. Transfer completes December 1, 2026.
• 

  17 February 2026

  Perstorp Expands Liquid Cooling Solutions for Data Centers

  Perstorp introduces Synplate™ and expands Synmerse™ for efficient, safe liquid cooling in data centers, enhancing performance and sustainability.
• 

  17 February 2026

  Huntsman Q4 2025 Earnings Report

  Q4 2025 net loss of $96M, adjusted net loss of $63M. Adjusted EBITDA at $35M. Free cash flow from operations at $20M, down from $108M last year.
• 

  17 February 2026

  Novo Nordisk: EU Approves Higher Wegovy® Dose for Obesity, 21% Average Weight Loss

  The EU approved a 7.2 mg Wegovy® dose for obesity. In studies, participants lost 21% body weight on average. Common side effects: nausea, diarrhea, vomiting, and dysaesthesia.
• 

  17 February 2026

  Genmab Releases 2025 Annual Report

  The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
• 

  17 February 2026

  FDA Approves Johnson & Johnson's Monthly EGFR Therapy RYBREVANT FASPRO

  FDA approves monthly dosing for RYBREVANT FASPRO, maintaining efficacy and reducing administration time and reactions compared to bi-weekly and IV schedules for EGFR-mutated NSCLC treatment.
• 

  17 February 2026

  Fluor 2025 Financial Results Summary

  2025 saw $754M in share repurchases, $12B in new awards, and a $25.5B backlog. Revenue hit $15.5B with a $51M net loss. $1.35B received from NuScale share sales in Q1 2026.
• 

  17 February 2026

  Fluor Sells 71M NuScale Shares for $1.35B, Plans to Trade Remaining 40M

  Fluor repurchased 17M shares for $700M and increased its share repurchase program by 30M shares. Further details to be discussed in the upcoming earnings call.
• 

  17 February 2026

  ElevenEs Secures Series B Funding with Caterpillar Venture Capital

  ElevenEs to start building a 1GWh LFP battery factory in Serbia, aiming for 2027 deliveries, creating 350 jobs, and advancing European battery tech.